Emulate Stock

emulatebio.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $202.31MM

Emulate is a biotechnology company developing advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.

Register To Buy and Sell Shares

For more details on financing and valuation for Emulate, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Emulate’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Emulate.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Geraldine Hamilton Ph.D
Chief Scientific Officer & President
Lewis Rowe
Chief Strategist
Daniel Levner Ph.D
Co-Founder & Chief Technology Officer
Harry Dhaliwal
Chief Financial Officer
David Coon
Chief Executive Officer
Donald Ingber Ph.D
Scientific Founder & Chair of the Scientific Advisory Board

Board Members

Eric Moessinger
Sharon Kedar
Aaron VanDevender Ph.D
Founders Fund
Frank Witney Ph.D
Donald Ingber Ph.D
Shlomo Melmed

Frequently Asked Questions About Emulate’s Stock

plusminus
Can you buy Emulate’s stock?
Emulate is not publicly traded on NYSE or NASDAQ in the U.S. To buy Emulate’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Emulate’s stock?
Yes, you can sell stock of a private company like Emulate. Forge can help you sell your Emulate stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Emulate’s stock price?
Emulate is a privately held company and therefore does not have a public stock price. However, you may access Emulate’s private market stock price with Forge Data.
plusminus
What is Emulate’s stock ticker symbol?
Emulate does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Emulate Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023
Emulate, Inc., a leading provider of next-generation in vitro models, today announced that it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.
How human ‘organs on a chip’ can help replace animal testing
Of the drugs that pass animal tests, more than 90% later fail in human clinical trials. But better technology could begin to replace the use of some animals—and make drug development cheaper and more effective.
Safer, faster, and more ethical drug development
For nearly a century, the drug trial process has remained the same. Researchers use animal testing before advancing drugs to human clinical trials. But this method is imperfect.
Updated on: Feb 28, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.